• 1.

    Jerke U, et al. Targeting cathepsin C in PR3-ANCA vasculitis. J Am Soc Nephrol 2022; 33:936947. doi: 10.1681/ASN.2021081112

  • 2.

    Rhee RL, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol 2016; 68:17111720. doi: 10.1002/art.39614

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Wallace ZS, et al. Nationwide trends in hospitalizations and in-hospital mortality in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2017; 69:915921. doi: 10.1002/acr.22976

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Mohammad AJ, et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2017; 44:14681475. doi: 10.3899/jrheum.160909

  • 5.

    Charlier C, et al. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 2009; 68:658663. doi: 10.1136/ard.2008.088302

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Goupil R, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8:416423. doi: 10.2215/CJN.07300712

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Jayne DRW, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599609. doi: 10.1056/NEJMoa2023386

Assessment of Cathepsin C Inhibition as an Effective Treatment for Anti-PR3 Antibody ANCA-Associated Vasculitis

Suneel M. Udani Suneel M. Udani, MD, FASN, is with Nephrology Associates of Northern Illinois and Indiana, Oak Brook, IL.

Search for other papers by Suneel M. Udani in
Current site
Google Scholar
PubMed
Close
Restricted access
Save